Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Vista, CA, March 18, 2026 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, and Mountaineer Biosciences today announced the launch of Subtilitas, a...
-
SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on...
-
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 AAD Meeting
-
A high concentration medical-grade polydeoxyribonucleotide (PDRN) formulation designed for advanced skin rejuvenation.
-
Transition brings enhanced patient experience and Botox, lip filler, and other med spa treatments.
-
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being...
-
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
-
Castle today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.
-
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
-
Castle announced the publication of a validation study in the Journal of the American Academy of Dermatology for its AdvanceAD-Tx test.